Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Am J Hematol. 2016 Sep 3;91(11):1096–1101. doi: 10.1002/ajh.24492

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Kaplan-Meier curve of subsequent overall survival after achieving EFS12 in FL patients (black=MER, red=Lyon) with expected survival in the age and sex matched general population (black dashed=MER/US, red dashed=Lyon/France); A: All patients, B: Immunochemotherapy treated patients, C: Rituximab monotherapy treated, D:Other therapy treated, E: Younger patients (Age <=60) F: Older patients.